Navarixin

DB11711InvestigationalSmall molecule

Navarixin has been investigated for the treatment of Asthma.

Mechanism: Pharmacologically active on C-X-C chemokine receptor type 1 and C-X-C chemokine receptor type 2
Curator reviewed
Formula / weight: C₂₂H₂₅N₃O₅ · 411.458 g/mol (avg)
Code names: SCH-527123

Resolves to

Compound

Structure

InChIKeyFIABAPOOXILNJX-CQSZACIVSA-NSMILESCCC[C@@H](NC1=C(NC2=CC=CC(C(=O)N(C)C)=C2O)C(=O)C1=O)C1=CC=C(C)O1

Targets

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Navarixin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.